natgillin/translations-raw huggingface dataset:
The compound of claim 5, wherein each one of said nitric oxide donor groups independently is of the formula -(C1-C6)alkylene-ONO2, or -O-(C1-C6)alkylene-ONO2, wherein said alkylene is optionally substituted by one or more -ONO2 groups; or is - ONO2. 
Spoj prema zahtjevu 5, naznačen time da svaka od navedenih skupina koja je donor dušikovog monoksida je neovisno -(C1-C6)alkilen-ONO2, ili -O-(C1-C6)alkilen-ONO2, pri čemu je navedeni alkilen po potrebi supstituiran s jednom ili više skupina -ONO2; ili je - ONO2.
linked to the carbon atom at position 3 of the pyrrolidine ring is the nitric oxide donor group -CH2-ONO2; and R1 linked to the carbon atom at position 4 of the pyrrolidine ring is H (herein identified compounds 1a1, 1a2 and 1a3, respectively); 
vezan na ugljikov atom u položaju 3 pirolidinskog prstena je skupina donor dušikovog oksida -CH2-ONO2; i R1 vezan na ugljikov atom u položaju 4 pirolidinskog prstena je H (ovdje identificirani kao spojevi redom 1a1, 1a2 i 1a3);
linked to the carbon atom at position 3 of the pyrrolidine ring is the nitric oxide donor group -ONO2; and R1 linked to the carbon atom at position 4 of the pyrrolidine ring is H (herein identified compounds 1b1, 1b2 and 1b3, respectively); 
vezan na ugljikov atom u položaju 3 pirolidinskog prstena je skupina donor dušikovog monoksida -ONO2; i R1 vezan na ugljikov atom u položaju 4 pirolidinskog prstena je H (ovdje identificirani kao spojevi redom 1b1, 1b2 i 1b3);
linked to the carbon atom at position 3 of the pyrrolidine ring is the nitric oxide donor group -CH2-ONO2; and R1 linked to the carbon atom at position 4 of the pyrrolidine ring is -CONH2 (herein identified compounds 16a1, 16a2 and 16a3, respectively); or 
vezan na ugljikov atom u položaju 3 pirolidinskog prstena je skupina donor dušikovog monoksida -CH2-ONO2; i R1 vezan na ugljikov atom u položaju 4 pirolidinskog prstena je -CONH2 (ovdje identificirani kao spojevi redom 16a1, 16a2 i 16a3); ili
linked to the carbon atom at position 3 of the pyrrolidine ring is the nitric oxide donor group -ONO2; and R1 linked to the carbon atom at position 4 of the pyrrolidine ring is -CONH2 (herein identified compounds 16b1, 16b2 and 16b3, respectively). 
vezan na ugljikov atom u položaju 3 pirolidinskog prstena je skupina donor dušikovog monoksida -ONO2; i R1 vezan na ugljikov atom u položaju 4 pirolidinskog prstena je -CONH2 (ovdje identificirani kao spojevi redom 16b1, 16b2 i 16b3).
each one of R1 linked to the carbon atoms at positions 3 and 5 of the piperidine ring is the nitric oxide donor group -CH2-ONO2; and R1 linked to the carbon atom at position 4 of the piperidine ring is H (herein identified compounds 6a1, 6a2 and 6a3, respectively); 
svaki od R1 vezan na ugljikove atome u položajima 3 i 5 piperidinskog prstena je skupina donor dušikovog monoksida -CH2-ONO2; i R1 vezan na ugljikov atom u položaju 4 piperidinskog prstena je H (ovdje identificirani kao spojevi redom 6a1, 6a2 i 6a3);
each one of R1 linked to the carbon atoms at positions 3 and 4 of the piperidine ring is the nitric oxide donor group -ONO2; and R1 linked to the carbon atom at position 5 of the piperidine ring is H (herein identified compounds 5b1, 5b2 and 5b3, respectively); 
svaki od R1 vezan na ugljikove atome u položajima 3 i 4 piperidinskog prstena je skupina donor dušikovog monoksida -ONO2; i R1 vezan na ugljikov atom u položaju 5 piperidinskog prstena je H (ovdje identificirani kao spojevi redom 5b1, 5b2 i 5b3);
(viii) each one of R1 linked to the carbon atoms at positions 3 and 5 of the piperidine ring is the nitric oxide donor group -ONO2; and R1 linked to the carbon atom at position 4 of the piperidine ring is H (herein identified compounds 6b1, 6b2 and 6b3, respectively); 
(viii) svaki od R1 vezan na ugljikove atome u položajima 3 i 5 piperidinskog prstena je skupina donor dušikovog monoksida -ONO2; i R1 vezan na ugljikov atom u položaju 4 piperidinskog prstena je H (ovdje identificirani kao spojevi redom 6b1, 6b2 i 6b3);
linked to the carbon atom at position 3 of the piperidine ring is the nitric oxide donor group -CH2-ONO2; R1 linked to the carbon atom at position 4 of the piperidine ring is -COOH; and R1 linked to the carbon atoms at position 5 of the piperidine ring is H (herein identified compounds 17a1, 17a2 and 17a3, respectively); 
vezan na ugljikov atom u položaju 3 piperidinskog prstena je skupina donor dušikovog monoksida -CH2-ONO2; R1 vezan na ugljikov atom u položaju 4 piperidinskog prstena je -COOH; i R1 vezan na ugljikov atom u položaju 5 piperidinskog prstena je H (ovdje identificirani kao spojevi redom 17a1, 17a2 i 17a3);
linked to the carbon atom at position 3 of the piperidine ring is the nitric oxide donor group -ONO2; R1 linked to the carbon atom at position 4 of the piperidine ring is -COOH; and R1 linked to the carbon atoms at position 5 of the piperidine ring is H (herein identified compounds 17b1, 17b2 and 17b3, respectively); or (xiii) R1 linked to the carbon atom at position 4 of the piperidine ring is the nitric oxide donor group -O-CH2-CH(ONO2)CH2-ONO2; and each one of R1 linked to the carbon atoms at positions 3 and 5 of the piperidine ring is H (herein identified compounds 181, 182 and 183, respectively). 
vezan na ugljikov atom u položaju 3 piperidinskog prstena je skupina donor dušikovog monoksida -ONO2; R1 vezan na ugljikov atom u položaju 4 piperidinskog prstena je -COOH; i R1 vezan na ugljikov atom u položaju 5 piperidinskog prstena je H (ovdje identificirani kao spojevi redom 17b1, 17b2 i 17b3); ili (xiii) R1 vezan na ugljikov atom u položaju 4 piperidinskog prstena je skupina donor dušikovog monoksida -OCH2-CH(ONO2)CH2-ONO2; i svaki od R1 vezan na ugljikove atome u položajima 3 i 5 piperidinskog prstena je H (ovdje identificirani kao spojevi redom 181, 182 i 183).
each one of R1 linked to the carbon atoms at positions 3 to 5 of the azepane ring is the nitric oxide donor group -CH2-ONO2; and R1 linked to the carbon atom at position 6 of the azepane ring is H (herein identified compounds 13a1, 13a2 and 13a3, respectively); 
svaki od R1 vezan na ugljikove atome u položajima 3 do 5 azepanskog prstena je skupina donor dušikovog monoksida -CH2-ONO2; i R1 vezan na ugljikov atom u položaju 6 azepanskog prstena je H (ovdje identificirani kao spojevi redom 13a1, 13a2 i 13a3);
each one of R1 linked to the carbon atoms at positions 3 to 5 of the azepane ring is the nitric oxide donor group -ONO2; and R1 linked to the carbon atom at position 6 of the azepane ring is H (herein identified compounds 13b1, 13b2 and 13b3, respectively); (xiii) each of R1 linked to the carbon atoms at positions 3, 4 and 6 of the azepane ring is the nitric oxide donor group -CH2-ONO2; and R1 linked to the carbon atom at position 5 of the azepane ring is H (herein identified compounds 14a1, 14a2 and 14a3, respectively); 
svaki od R1 vezan na ugljikove atome u položajima 3 do 5 azepanskog prstena je skupina donor dušikovog monoksida -ONO2; i R1 vezan na ugljikov atom u položaju 6 azepanskog prstena je H (ovdje identificirani kao spojevi redom 13b1, 13b2 i 13b3); (xiii) svaki od R1 vezan na ugljikove atome u položajima 3, 4 i 6 azepanskog prstena je skupina donor dušikovog monoksida -CH2-ONO2; i R1 vezan na ugljikov atom u položaju 5 azepanskog prstena je H (ovdje identificirani kao spojevi redom 14a1, 14a2 i 14a3);
each of R1 linked to the carbon atoms at positions 3, 4 and 6 of the azepane ring is the nitric oxide donor group -ONO2; and R1 linked to the carbon atom at position 5 of the azepane ring is H (herein identified compounds 14b1, 14b2 and 14b3, respectively); 
svaki od R1 vezan na ugljikove atome u položajima 3, 4 i 6 azepanskog prstena je skupina donor dušikovog monoksida -ONO2; i R1 vezan na ugljikov atom u položaju 5 azepanskog prstena je H (ovdje identificirani kao spojevi redom 14b1, 14b2 i 14b3);
A pharmaceutical composition comprising a compound according to any one of claims 1 to 11, or an enantiomer, diastereomer, racemate, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1 do 11, ili njegov enantiomer, dijastereomer, racemat, ili farmaceutski prihvatljivu sol, i farmaceutski prihvatljivi nosač.
The pharmaceutical composition of claim 12, for use in intravenous, intraarterial, intramuscular, intraperitoneal, intrathecal, intrapleural, intratracheal, subcutaneous, topical, inhalational, or oral administration. 
Farmaceutski sastav prema zahtjevu 12, za upotrebu pri intravenskoj, intraarterijskoj, intramuskularnoj, intraperitonealnoj, intratekalnoj, intrapleuralnoj, intratrahealnoj, potkožnoj, topikalnoj, inhalacijskoj ili oralnoj primjeni.
R6b is hydrogen, or together with R7b a -CH2 group, or a double bound; 
b je vodik, ili zajedno s R7b je -CH2 skupina, ili dvostruka veza;
characterized in that the oxidation is performed with at least 3 molar equivalents of alkali hypochlorite, organic hypochlorite or 2-3 molar equivalents of alkaline-earth hypochlorite as an oxidizing agent in the presence of catalytic amounts of a 2,2,6,6-tetramethylpiperidine-N-oxide derivative at a pH of at least 8.0, in a two-phase solvent-water mixture, whereby the solvent is selected such that both the TEMPO derivative and the compounds of formula la can be well dissolved therein. 
naznačen time da se provodi oksidacija, s najmanje 3 molarna ekvivalenta alkalijskog hipoklorita, organskog hipoklorita ili 2-3 molarna ekvivalenta zemnoalkalijskog hipoklorita kao oksidacijskog sredstva u prisutnosti katalitičkih količina derivata 2,2,6,6-tetrametilpiperidin-N-oksida kod pH od najmanje 8.0, u dvofaznoj smjesi otapalo-voda, pri čemu je otapalo odabrano tako da se oba TEMPO derivat i spojevi s formulom Ia u njemu mogu dobro otopiti.
R6a is hydrogen, or together with R7a a -CH2 group; 
a je vodik, ili zajedno s R7a je skupina -CH2;
R6b is hydrogen, or together with R7b a -CH2 group, or a double bound; 
b je vodik, ili zajedno s R7b je skupina -CH2, ili dvostruko vezan;
R6b is hydrogen, or together with R6b a -CH2 group; 
b je vodik, ili zajedno s R6b je skupina -CH2;
is hydrogen, together with R11 a double bond, or together with R11 an epoxy group -O-; 
je vodik, zajedno s R11 je dvostruka veza, ili zajedno sa R11 je epoksi skupina -O-;
is hydrogen, together with R15 a -CH2 group or a double bond; 
je vodik, zajedno s R15 je skupina -CH2 ili dvostruka veza;
comprising the oxidation of a compound of formula la in which R6a, R6b, R7a, R7b, R9, R10, R11, R15, R16 have the same meaning as in formula IIa, characterized in that the oxidation is performed with at least 3 molar equivalents of alkali hypochlorite, organic hypochlorite or 2-3 molar equivalents of alkaline-earth hypochlorite as an oxidizing agent in the presence of catalytic amounts of a 2,2,6,6-tetramethylpiperidine-N-oxide derivative at a pH of at least 8.0, in a two-phase solvent-water mixture, whereby the solvent is selected such that both the TEMPO derivative and the compounds of formula la can be well dissolved therein. 
koji obuhvaća oksidaciju spoja formule Ia [image] u kojoj a, R6b, R7a, R7b, R9, R10, R11, R15, R16 imaju isto značenje kao u formuli IIa, naznačen time da se oksidacija provodi s barem 3 molarna ekvivalenta alkalijskog hipoklorita, organskog hipoklorita ili 2-3 molarna ekvivalenta zemnoalkalijskog hipoklorita kao oksidirajućeg sredstva u prisutnosti katalitičkih količina derivata 2,2,6,6-tetrametilpiperidin-N-oksida uz pH od najmanje 8.0, u dvofaznoj smjesi otapalo-voda, pri čemu se otapalo bira tako da i TEMPO derivat i spojevi formule la mogu u njemu biti dobro otopljeni.
represents H or halogen; represents (C3-C4)alkynyloxy or the group M; 
predstavlja H ili halogen; predstavlja (C3-C4)alkiniloksi ili skupinu M;
represents H or halogen; M is one of the groups MA, MB, MC and MD represented hereafter 
predstavlja H ili halogen; M je jedna od skupina MA, MB, MC i MD predstavljena ovdje kako slijedi:
M is the one of the groups MA, MB, MC and MD represented hereafter 
M je jedna od skupina MA, MB, MC i MD predstavljena ovdje kako slijedi:
M is one of the groups MA and MB represented below 
M je jedna od skupina MA i MB predstavljena dolje:
A compound of formula I according to one of claims 1 to 4, wherein R2 represents the group MA; 
Spoj formule I prema jednom od zahtjeva 1 do 4, naznačen time, da R2 predstavlja skupinu MA;
A compound of formula I according to one of claims 1 to 4, wherein R2 represents the group MB; 
Spoj formule I prema jednom od zahtjeva 1 do 4, naznačen time, da R2 predstavlja skupinu MB;
A compound of formula I according to one of claims 1 to 4, wherein R2 represents the group MC; 
Spoj formule I prema jednom od zahtjeva 1 do 4, naznačen time, da R2 predstavlja skupinu MC;
A pharmaceutical composition containing, as active principle, a compound of formula I as defined in one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient. 
Farmaceutski pripravak, naznačen time, da kao djelatni sastojak, obuhvaća spoj koji je definiran u jednom od zahtjeva 1 do 13, ili njegovu farmaceutski prihvatljivu sol, te najmanje jedno terapeutski inertno pomoćno sredstvo.
A floating structure according to claim 1, characterized in that the recess (22; 221; 222) is in the form of a trough with walls and a bottom. 
Plutajuća konstrukcija prema zahtjevu 1, naznačena time da je udubljenje (22; 221; 222) u obliku korita sa zidovima i dnom.
A floating structure according to claim 1, characterized in that the space unit (3) is for example a cabin, an accommodation space, a public space, or a bathroom. 
Plutajuća konstrukcija prema zahtjevu 1, naznačena time, da je prostorna jedinica (3) primjerice kabina, smještajni prostor, javni prostor ili kupaonica.
A method according to claim 8, characterized in that the recess (22; 221; 222) is formed as a trough with walls and a bottom. 
Postupak prema zahtjevu 8, naznačen time da je udubljenje (22; 221; 222) oblikovano kao korito sa zidovima i dnom.
represents a hydrogen or fluorine atom or a trifluoromethyl group; 
predstavlja vodikov ili fluorov atom ili skupinu trifluorometil;
A compound of formula (I) as defined in claim 1 selected from the group consisting of: 
Spoj s formulom (I) kako je definirano u zahtjevu 1 naznačen time da je odabran iz skupine koja sadrži:
The method of claim 1, wherein the quenching with water lowers the temperature of the off-gas by more than 50° C. 
Postupak sukladno patentnom zahtjevu 1 ili 2, pri čemu hlađenje vodom spušta temperaturu toka plina za više od 50°C.
The method of claim 3, wherein the quenched off-gas has a temperature below about 45° C. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1-3, pri čemu ohlađeni sagorjeli plin ima temperaturu ispod oko 45°C.
A ship propulsion system, comprising 
Brodski propulzijski sustav, koji sadrži:
an electrolysis chamber for producing hydrogen gas and oxygen gas, 
komora za elektrolizu (20) za proizvodnju plina vodika i kisika,
The ship propulsion system as defined in claim 6, wherein: the controller is configured to: use a boost pressure of the internal combustion engine as a momentary property of the internal combustion engine operation in dependence on which the at least one of: the electric current, the water introduction or the pumping capacity of the vacuum pump is controlled, a boost pressure of the internal combustion engine (50), and 
Propulzijski sustav brodova sukladno zahtjevu 6, naznačen time, da sredstva za upravljanje (10) su konfigurirana tako da koriste trenutna svojstva rada motora s unutarnjim izgaranjem u ovisnosti od električne struje, unosa vode i/ili kapaciteta vakuumske pumpe (25), a pritisak motora s unutarnjim izgaranjem (50) i upravljačka sredstva (10) su konfigurirana tako da električna struja i kapacitet crpke budu veći, što je veći poticajni pritisak.
cultivating the resulting cell in an appropriate medium and transferred into a synchronised recipient for generating a transgenic animal. 
kultiviranje rezultirajuće stanice u odgovarajućem mediju i prenošenje u nastalu stanicu u sinkronizirani primatelj za generiranje transgenične ne-humane životinje.
The method of any preceding claim, further comprising the use of a second meganuclease, wherein the second meganuclease recognizes a second meganuclease target sequence present in or proximal to the endogenous Ig locus and selectively cleaves the endogenous Ig locus together with the first meganuclease but at a site distinct from that of the first meganuclease, thereby inactivating at least one endogenous Ig locus. 
Postupak sukladno bilo kojem prethodnom patentnom zahtjevu, naznačen time, da sukladno bilo kojem prethodnom patentnom zahtjevu, nadalje obuhvaća uporabu druge meganukleaze, pri čemu druga meganukleaza prepoznaje drugu ciljnu sekvencu meganukleaze prisutnu u ili proksimalnom endogenom Ig lokusu i selektivno cijepa endogeni Ig lokus zajedno s prvom meganukazom, ali na mjestu različitom od prve meganukleaze, čime se inaktivira najmanje jedan endogeni Ig lokus
wherein the animal is capable of producing an antibody having a human idiotype. 
pri čemu je životinja sposobna proizvesti protutijelo koje ima ljudski idiotip.
of a nucleic acid which codes for the tumor-associated antigen, and/or of the tumor-associated antigen, in a biological sample, with said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of: 
Farmaceutski pripravak za primjenu u postupku liječenja, koja se sastoji od antitijela koje se veže za ekstracelularni dio antigena povezanog s tumorom, Navedeni s tumorom povezani antigen koji ima sekvencu koju kodira nukleinska kiselina koja se odabire iz skupine sastavljene od:
The antibody for use as in claim 6, wherein the autoimmune or inflammatory disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, proliferative lupus glomerulonephritis, inflammatory bowel disease (IBD), psoriasis, idiopathic thrombocytopenic purpura (ITP), Crohn's Disease and systemic lupus erythematosus (SLE), Hashimoto's thyroiditis, primary myxoedema, thyrotoxicosis/Graves disease, pernicious anaemia, autoimmune atrophic gastritis, autoimmune carditis, Addison's disease, premature menopause, type 1-diabetes mellitus, Good pasture's syndrome, myasthenia gravis, autoimmune haemolytic anaemia, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis (HBs Ag negative), cryptogenic cirrhosis, Sjogren's syndrome, dermatomyositis, scleroderma, mixed tissues connective disease, discoid lupus erythematosus, and systemic vasculitis. 
Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 3, naznačeno time što se autoimunu ili upalnu bolest bira iz skupine koju čine reumatoidni artritis, multipla skleroza, proliferativni lupus s glomerulonefritisom, upalna bolest crijeva (IBD), psorijaza, idiopatska trombocitopenična purpura (ITP), Crohnova bolest i sistemni eritematozni lupus (SLE), Hashimotoov tireoiditis, primarni miksoedem, tirotoksikoza/Gravesova bolest, perniciozna anemija, autoimuni atrofični gastritis, autoimuni karditis, Addisonova bolest, prijevremena menopauza, dijabetes melitus tip 1, Goodpastureov sindrom, mijastenija gravis, autoimuna hemolitična anemija, idiopatska leukopenija, primarna bilijarna ciroza, aktivni kronični hepatitis (HBs Ag negativni), kriptogena ciroza, Sjögrenov sindrom, dermatomiozitis, skleroderma, miješana bolest vezivnih tkiva, diskoidni eritematozni lupus, te sistemni vaskulitis.
The antibody for use as in any one of claims 5-8, wherein said antibody is administered by a parenteral route, intravenous route or subcutaneous route of administration. 
Protutijelo namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 2-5, naznačeno time što se navedeno protutijelo primjenjuje parenteralnim načinom, intravenskim načinom ili supkutanim načinom primjene.
Use of the antibody or antibody fragment of any one of the claims 1 to 5 in research or in vitro diagnostic applications, wherein said antibody or antibody fragment comprises a label such as a radiolabel, a fluorophore, a chromophore, an imaging agent or a metal ion. 
Uporaba humaniziranog bispecifičnog protutijela iz bilo kojeg od patentnih zahtjeva 1 do 4 za istraživačke primjene, naznačena time da navedeno protutijelo sadrži oznaku kao što je radioaktivna oznaka, fluorofor, kromofor, sredstvo za snimanje ili metalni ion.
The pharmaceutically acceptable liquid composition of claim 1, wherein said composition has a pH of 9.2 to 9.8 at 25°C. 
Farmaceutski prihvatljiv tekući sastav iz zahtjeva 1, naznačeno time da spomenuti sastav ima pH vrijednost od 9,2 do 9,8 na 25°C.
The pharmaceutically acceptable liquid composition of any one of claims 1 to 6, further comprising an agent that inhibits the formation of oxidation products. 
Farmaceutski prihvatljiv tekući sastav iz bilo kojeg zahtjeva 1 do 3, nadalje sadržeći agent koji inhibira stvaranje produkata oksidacije.
The pharmaceutically acceptable liquid composition of claim 4, wherein the agent is L-cysteine, N-acetylcysteine (NAC), gluthatione (GSH), Na2-EDTA, Na2-EDTA-Ca, sodium bisulfite, or combinations thereof. 
Farmaceutski prihvatljiv tekući sastav iz zahtjeva 4, naznačeno time da je agent L-cistein, N-acetilcistein (NAC), glutation (GSH), Na2-EDTA, Na2-EDTA-Ca, natrijev bisulfit, ili kombinacije istih.
The pharmaceutically acceptable liquid composition of claim 1 or 2, comprising: 
Farmaceutski prihvatljiv tekući sastav iz zahtjeva 1 ili 2, sadržeći:
6% by weight levodopa, 1.5% by weight carbidopa, 1% by weight ascorbic acid or Na-ascorbate, and 14.8%, 15.8%, 16% or 16.8%, by weight arginine; 
6% masenog udjela levodopa, 1,5% masenog udjela karbidopa, 1% masenog udjela askorbinske kiseline ili natrijevog askorbata, i 14,8%, 15,8%, 16% ili 16,8% masenog udjela arginina;
7% by weight levodopa, 2% by weight carbidopa, 1 % by weight ascorbic acid or Na ascorbate, and 17.8% by weight arginine. 
7% masenog udjela levodopa, 2% masenog udjela karbidopa, 1% masenog udjela askorbinske kiseline ili natrijevog askorbata, i 17,8% masenog udjela arginina.
The pharmaceutically acceptable liquid composition of any one of claims 1 to 8, formulated for continuous subcutaneous, transdermal, intraduodenal or intravenous administration. 
Farmaceutski prihvatljiv tekući sastav iz bilo kojeg zahtjeva 1 do 6, formuliran za kontinuiranu subkutanu, transdermalnu, intraduodenalnu ili intravenoznu primjenu.
The pharmaceutically acceptable liquid composition of any one of claims 1 to 9, for use in treatment of a neurological or movement disorder such as Parkinson's disease. 
Farmaceutski prihvatljiv tekući sastav iz bilo kojeg zahtjeva 1 do 7, za upotrebu u liječenju neuroloških poremećaja ili poremećaja pokreta poput Parkinsonove bolesti.
A method according to claim 1, wherein the compound of formula (I) is selected from the group consisting of: 
Postupak prema zahtjevu 1, naznačen time da je spoj s formulom (I) odabran iz skupine koju čine:
A method according to claim 1 or claim 2 wherein the strain of fungi is resistant to at least one fungicide selected in the list consisting of benodanil, bixafen, boscalid, carboxin, fenfuram, fluopyram, flutolanil, fluxapyroxad, furametpyr, isopyrazam, mepronil, oxycarboxin, penflufen, penthiopyrad, sedaxane, trifluzamid, benzovindiflupyr, isofetamid. 
Postupak prema zahtjevu 1 ili zahtjevu 2 naznačen time da je soj gljivica otporan na barem jedan fungicid odabran s popisa koji sadrži benodanil, biksafen, boskalid, karboksin, fenfuram, fluopiram, flutolanil, fluksapiroksad, furametpir, izopirazam, mepronil, oksikarboksin, penflufen, pentiopirad, sedaksan, trifluzamid, benzovindiflupir, izofetamid.